KemPharm, Inc. to Present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY
December 03, 2015 09:27 ET
|
KemPharm
CORALVILLE, Iowa, Dec. 3, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Reports Q3 2015 Results
November 12, 2015 16:14 ET
|
KemPharm
Recent Clinical Development Highlights:
Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen...
KemPharm, Inc. to Report Third Quarter 2015 Results
November 05, 2015 16:05 ET
|
KemPharm
CORALVILLE, Iowa, Nov. 5, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP
October 21, 2015 16:05 ET
|
KemPharm
Positive Results From Second Intranasal Human Abuse Liability Clinical Trial Reaffirm Properties of KP201/APAP
Conference Call and Live Audio Webcast Scheduled for Today at 5:00 p.m....
KemPharm Enhances U.S. and Global Intellectual Property Estate
October 13, 2015 07:33 ET
|
KemPharm
CORALVILLE, Iowa, Oct. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
September 30, 2015 07:31 ET
|
KemPharm
CORALVILLE, Iowa, Sept. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates
September 24, 2015 08:30 ET
|
KemPharm
CORALVILLE, Iowa, Sept. 24, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm to Highlight the Potential of Prodrugs at the 9th Annual Pain & Migraine Therapeutics Summit
September 23, 2015 08:30 ET
|
KemPharm
CORALVILLE, Iowa, Sept. 23, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm Data to be Presented at PAINWeek 2015
September 08, 2015 07:03 ET
|
KemPharm
CORALVILLE, Iowa, Sept. 8, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
August 13, 2015 16:05 ET
|
KemPharm
Results from First of Two Intranasal Human Abuse Liability Clinical Studies Indicate KP201 Exhibits Significantly Lower Exposure to Hydrocodone When Administered Intranasally
Conference Call and...